By API User
This introduction brings one of the world’s most advanced exosome technologies to New Zealand, with two exclusive events set to take place in: • Auckland – July 15, 2025 | The Boathouse, Park Hyatt Auckland, from 6:30pm • Christchurch – July 17, 2025 | Chateau on the Park, DoubleTree by Hilton, from 6:30pm These … Continued
By API User
BUFFALO, NEW YORK / ACCESS Newswire / June 23, 2025 / ZeptoMetrix® is pleased to announce the launch of NATtrol™ Influenza A H5N1 Quantitative Stock, a groundbreaking advancement in molecular diagnostic quality assurance. Leveraging phage-like particle encapsulated RNA technology, this product sets a new standard for accuracy and reliability in avian influenza (H5N1) detection, addressing … Continued
By API User
The Therapeutic Good Administration has granted Magellan Stem Cells a stem-cell manufacturing licence. The decision will help reduce Australia’s reliance on overseas manufacturing and encourage the commercialisation of innovative Australian cellular therapeutics, Magellan Stem Cells Chief Medical Officer, Associate Professor Julien Freitag said. “The licence from the federal regulator places Magellan as one of the … Continued
By API User
INOVIQ Limited (ASX: IIQ) is pleased to announce a major milestone in its exosome therapeutic program. In recent in vitro studies, INOVIQ’s CAR-exosomes demonstrated exceptional efficacy, killing 88% of TNBC and lung cancer cells within 96 hours. This marks a major success for INOVIQ’s new platform, showing it works well against two solid tumours. The … Continued
By API User
Cleo Diagnostics shares its updated June 2025 corporate presentation outlining the Company’s strategy and progress on “Pioneering the Transformation of Ovarian Cancer Detection.” The clinical unmet need for a screening solution for Ovarian Cancer is urgent. Critically, no effective screening test currently exists, with the only way to definitively diagnose Ovarian Cancer … Continued
By API User
June 2025 – Australia As global industry races to decarbonise, an unlikely hero is emerging from the Australian landscape: the pongamia tree. Recently highlighted in Rio Tinto’s ambitious biofuels project, this native species is now at the centre of a broader movement, one that includes sustainable bioplastics, climate-resilient agriculture, and nature-based solutions to emissions reduction. … Continued
By API User
INOVIQ Limited (ASX: IIQ) is pleased to announce game-changing results from its EXO-OC™ ovarian cancer test presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on 1 June 2025 in Chicago. The Poster titled Early detection of ovarian cancer: An accurate high-throughput extracellular vesicle test is copied below. The test uses proprietary technology … Continued
By API User
2 June 2025 – Melbourne, Australia | ReNerve Limited (ASX:RNV) has today announced a strategic partnership with US-based Berkeley Biologics, focused on developing and commercialising two new tissue-based product ranges, which will significantly expand its surgical offering in the peripheral nerve injury (PNI) space. The collaboration between the organisations will see both product lines launched … Continued
By API User
28 May 2025 – Sydney, Australia | ReNerve Limited has received marketing approval in Bahrain for its FDA-cleared NervAlign® Nerve Cuff™ product for peripheral nerve injuries (PNIs), marking its first regulatory milestone in the Middle East with its latest partner, Union MediScience B.S.C. The approval will allow for the commercial rollout in Bahrain, and lays … Continued
By API User
Highlights: OncoSil Medical Limited (ASX:OSL) (OncoSil or Company) has received firm commitments for an $8.7m capital raise supported by existing and new shareholders, including strong support from several Australian institutional investors. Existing substantial shareholder, Pengana High Conviction Equities Fund was a cornerstone investor in the capital raise and will increase their holding in Oncosil following completion … Continued
